一种含有天然多糖的新型复合水凝,来自Atractylodes macrocephala Koidz. 用于糖尿病患者的伤口愈合
Weiwei Yao1, Yongxin Mao1, Youyan Zeng1
1The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine (Institute of Chinese Medicine), MOE Key Laboratory of Glucolipid Metabolic Disorder, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, China.
Journal of ethnopharmacology
|November 2, 2025
概括
来自Atractylodes macrocephala Koidz. 的多糖. (AM) 通过促进细胞生长和减少炎症来加速糖尿病伤口愈合. 含AMP的水凝对糖尿病复杂的伤口护理具有显著的治疗潜力.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 伤口治愈研究研究 伤口治愈研究
背景情况:
- 糖尿病伤口表现出受损的愈合,需要新的治疗策略.
- 吸引类巨头科伊兹科伊兹. (AM) 具有抗炎和抗氧化特性,表明糖尿病伤口治疗的潜力.
- 需要阐明AM用于伤口愈合的特定生物活性成分和机制.
研究的目的:
- 从AM (AMP) 中提取和描述多糖类.
- 开发含AMP的复合水凝,用于糖尿病伤口护理.
- 研究AMP及其水凝在促进糖尿病伤口愈合方面的疗效和潜在机制.
主要方法:
- 从AM中提取和净化AMP,然后进行全面的表征 (UV-Vis,FT-IR,HPGPC,SEM).
- 在体外评估AMP对人类静脉内皮细胞 (HUVEC) 和巨细胞炎症反应的影响.
- 装有AMP的复合水凝 (SEM,风学) 的制造和表征.
- 在糖尿病小鼠伤口模型中对水凝疗效的体内评估,包括组织学和分子分析.
主要成果:
- 鉴定AMP是一种均的异多聚糖化物 (3454Da),在高葡萄糖条件下增强HUVEC增殖,迁移和管状形成.
- AMP调节了巨细胞的反应,减少了M1型炎症,促进了M2极化.
- 含AMP的复合水凝表现出有利的结构,机械和生物相容性,通过调节CD31,TNF-α和NF-κB表达,显著加快糖尿病伤口愈合.
结论:
- AMP显示出与糖尿病伤口环境相关的显著的治疗性质.
- 装有AMP的复合水凝代表了一种有前途的先进材料,用于有效的糖尿病伤口治疗.
- 对基于AMP的治疗方法的进一步研究可能会导致糖尿病伤病患者的临床结果改善.
相关概念视频
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...